Shanta Bantia

Shanta Bantia

Company: Nitor Therapeutics

Job title: President and Chief Executive Officer


Dr. Shanta Bantia has more than 25 years of experience in drug discovery and early clinical development. She has advanced number of compounds into the clinic in the areas of oncology, virology and inflammation which led to approval of RAPIVAB for the treatment of influenza and Mundesine (approved in Japan) for the treatment of relapsed/refractory peripheral T-cell lymphoma. In addition, advanced Galidesivir (BCX4430), viral RNA polymerase inhibitor, as broad spectrum anti-viral agent (BSAV) for the treatment of Marburg Ebola and other deadly viral diseases including COVID-19. Her current research interest is focused on developing novel small molecule immunotherapies targeting various pattern recognition receptors.


Purine nucleoside phosphorylase inhibitors as TLR agonist 2:50 pm

• Purine Nucleoside Phosphorylase (PNP) deficiency in humans causes lymphopenia and that led to development of PNP inhibitors as immunosuppressive agents. • Careful evaluation of clinical history of PNP deficient patients and clinical experience with PNP inhibitors together with new experimental data we have discovered that inhibition of PNP activates immune system through elevation of…Read more

day: Online Conference

Live Q&A 3:10 pm

Read more

day: Online Conference

© Copyright 2018 Hanson Wade | Design and site by Event Engine | Hanson Wade Limited is registered in England & Wales, number 06752216.
Registered Office: Suite A, 6 Honduras Street, London EC1Y 0TH.